Alternate Dosing Regimens for Vismodegib: A Literature Review.

IF 4.7 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2025-07-01 Epub Date: 2025-05-26 DOI:10.1007/s11864-025-01332-6

Kevin Yang, Hoang Ho-Pham, Collin Pieper, Conway C Huang, Daniel J Bergman

引用次数: 0

Abstract

Opinion statement: Vismodegib is a hedgehog inhibitor used in the treatment of basal cell carcinomas and basal cell nevus syndrome. However, treatment is associated with significant side effects that can impact compliance, including fatigue, muscle cramps, hair loss, and taste disturbance. Multiple strategies to change dosing frequency have been implemented to improve the tolerability. Vismodegib may be administered with non-daily dosing or with drug holidays to improve the side effects associated with administration. Intermittent dosing of vismodegib may be more appropriate for patients with locally advanced BCC and drug holidays may be more suited for patients with basal cell nevus syndrome. The most appropriate strategy in each case though will ultimately depend on patient preference.

查看原文本刊更多论文

维莫德吉的替代给药方案：文献综述。

观点声明：Vismodegib是一种用于治疗基底细胞癌和基底细胞痣综合征的hedgehog基因抑制剂。然而，治疗伴有影响依从性的显著副作用，包括疲劳、肌肉痉挛、脱发和味觉障碍。已经实施了多种改变给药频率的策略来提高耐受性。Vismodegib可以非每日给药或药物假期给药，以改善与给药相关的副作用。间歇性给药vismodegib可能更适合局部晚期BCC患者，而药物假期可能更适合基底细胞痣综合征患者。但每种情况下最合适的策略最终取决于患者的偏好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.